QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
NASDAQ:ASND

Ascendis Pharma A/S (ASND) Stock Price, News & Analysis

$158.20
+1.06 (+0.67%)
(As of 02/22/2024 ET)
Today's Range
$156.16
$160.05
50-Day Range
$120.89
$158.20
52-Week Range
$64.33
$160.05
Volume
361,104 shs
Average Volume
445,447 shs
Market Capitalization
$9.13 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$158.29

Ascendis Pharma A/S MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
0.1% Upside
$158.29 Price Target
Short Interest
Healthy
5.08% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.69mentions of Ascendis Pharma A/S in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.92) to ($1.33) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.66 out of 5 stars

Medical Sector

677th out of 934 stocks

Pharmaceutical Preparations Industry

312th out of 425 stocks


ASND stock logo

About Ascendis Pharma A/S Stock (NASDAQ:ASND)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

ASND Stock Price History

ASND Stock News Headlines

Ascendis Pharma A/S - ADR
Clear Buy, Sell, or Hold Recommendation on any Stock, FREE
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
How Is The Market Feeling About Ascendis Pharma?
The perfect AI stock under $10
Normally, bringing a new drug to market takes an average of 10 years and between $2.5 and $12 billion. However, new AI technology has the potential to make the process up to 1000 times faster. This #1 AI company is at the forefront of it all.
Ascendis Pharma price target raised by $18 at Wedbush, here's why
Ascendis Pharma: Strong Buy on Robust Sales and Innovative Pipeline
Ascendis Pharma's Ambitious Vision 2030
See More Headlines
Receive ASND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
2/22/2024
Next Earnings (Estimated)
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ASND
Employees
879
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$158.29
High Stock Price Target
$225.00
Low Stock Price Target
$113.00
Potential Upside/Downside
-0.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

Net Income
$-521,070,000.00
Net Margins
-180.61%
Pretax Margin
-177.77%
Return on Equity
-16,574.15%

Debt

Sales & Book Value

Annual Sales
$288.08 million
Book Value
($2.73) per share

Miscellaneous

Free Float
34,624,000
Market Cap
$9.19 billion
Optionable
Optionable
Beta
0.50
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Jan Moller Mikkelsen (Age 64)
    President, CEO, Member of Executive Board & Executive Director
  • Mr. Scott T. Smith (Age 50)
    CFO, Executive VP & Member of Executive Board
  • Ms. Lotte Sonderbjerg (Age 63)
    Executive VP, Chief Administrative Officer & Member of the Executive Board
  • Mr. Michael Wolff Jensen L.L.M. (Age 53)
    Executive VP, Chief Legal Officer & Member of the Executive Board
  • Mr. Peter Rasmussen (Age 55)
    VP of Finance & Principal Accounting Officer
  • Mr. Timothy J. Lee
    Senior Director of Investor Relations
  • Mr. Flemming Steen Jensen (Age 63)
    Executive Vice President of Product Supply & Quality - Endocrinology Rare Diseases
  • Dr. Kennett Sprogoe Ph.D. (Age 45)
    Executive Vice President of Research & Product Development
  • Dr. Stina Singel M.D. (Age 50)
    Ph.D., Executive VP & Head of Clinical Development for Oncology
  • Mr. Joseph Kelly (Age 55)
    Head of U.S. Commercial of Endocrinology














ASND Stock Analysis - Frequently Asked Questions

Should I buy or sell Ascendis Pharma A/S stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ASND shares.
View ASND analyst ratings
or view top-rated stocks.

What is Ascendis Pharma A/S's stock price target for 2024?

10 Wall Street analysts have issued 12 month target prices for Ascendis Pharma A/S's shares. Their ASND share price targets range from $113.00 to $225.00. On average, they expect the company's stock price to reach $158.29 in the next year. This suggests a possible upside of 0.1% from the stock's current price.
View analysts price targets for ASND
or view top-rated stocks among Wall Street analysts.

How have ASND shares performed in 2024?

Ascendis Pharma A/S's stock was trading at $125.95 at the start of the year. Since then, ASND shares have increased by 25.6% and is now trading at $158.20.
View the best growth stocks for 2024 here
.

Are investors shorting Ascendis Pharma A/S?

Ascendis Pharma A/S saw a decline in short interest in the month of January. As of January 31st, there was short interest totaling 2,930,000 shares, a decline of 9.8% from the January 15th total of 3,250,000 shares. Based on an average trading volume of 567,500 shares, the short-interest ratio is presently 5.2 days.
View Ascendis Pharma A/S's Short Interest
.

When is Ascendis Pharma A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our ASND earnings forecast
.

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) released its earnings results on Tuesday, November, 9th. The biotechnology company reported ($1.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.60) by $1.13. The biotechnology company earned $1.31 million during the quarter, compared to the consensus estimate of $1.60 million. Ascendis Pharma A/S had a negative trailing twelve-month return on equity of 16,574.15% and a negative net margin of 180.61%. During the same quarter last year, the business posted ($2.70) EPS.

What other stocks do shareholders of Ascendis Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD), Incyte (INCY), Exelixis (EXEL), GW Pharmaceuticals (GWPH) and NVIDIA (NVDA).

When did Ascendis Pharma A/S IPO?

(ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager.

Who are Ascendis Pharma A/S's major shareholders?

Ascendis Pharma A/S's stock is owned by a variety of institutional and retail investors. Top institutional investors include Artisan Partners Limited Partnership (9.96%), Westfield Capital Management Co. LP (6.98%), Avoro Capital Advisors LLC (6.51%), Capital International Investors (3.78%), Massachusetts Financial Services Co. MA (2.63%) and Price T Rowe Associates Inc. MD (2.50%).

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ASND) was last updated on 2/22/2024 by MarketBeat.com Staff